首页 / 院系成果 / 成果详情页

Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer in extensive stage 期刊论文

编号：

ab1040e3-2d67-49d1-b895-7063fae462cc
作者：

Ding X;Cao H;Chen X;Zhao Y;Jin H;Niu C;Ma K;Liu Z;Chen J;Wang X;Yang L;He H;Han W;Li D;Tian H;Li W(李薇); Cui J;
地址：

[Ding X.; Cao H.; Chen X.; Zhao Y.; Jin H.; Niu C.; Ma K.; Liu Z.; Wang X.; Yang L.; He H.; Han W.; Li D.; Tian H.; Li W.,; Cui J.,] Cancer Center, The First Hospital of Jilin University, No. 71, Xinmin Street, Changchun, China. ;[Chen J.] Institute of Translational Medicine, The First Hospital of Jilin University, No. 71, Xinmin Street, Changchun, China.
语种：

英文
期刊：

Journal of Cellular Immunotherapy 2016 年 2 卷 1 期 (36 - 43) ; 1 Mar 2016
收录：
摘要：

Background: Small cell lung cancer (SCLC) is the most devastating type of human lung cancer. Patients usually present with disseminated disease to many organs (extensive stage). This study was to investigate the efficacy and safety of cellular immunotherapy (CIT) with autologous natural killer (NK), γδT, and cytokine-induced killer (CIK) cells as maintenance therapy for extensive-stage SCLC (ES-SCLC) patients. Methods: A pilot prospective cohort study was conducted with ES-SCLC patients who had responded to initial chemotherapy. Patients received either CIT as maintenance therapy (CIT group), or no treatment (control group). Progression-free survival (PFS), overall survival (OS), and adverse effects were compared. Results: Forty-nine patients were recruited in this study, with 19 patients in the CIT group and 30 patients in the control group. The patient characteristics of the 2 groups were comparable except for age, as patients in the CIT group were older than those in the control group (P < 0.05). PFS in the CIT group was superior to the control group (5 vs. 3.1 months, P = 0.020; HR, 0.489, 95% CI, 0.264-0.909, P = 0.024). OS of the CIT group was also longer than that of the control group (13.3 vs. 8.2 months, P = 0.044; HR, 0.528, 95% CI, 0.280-0.996, P = 0.048, respectively). No significant adverse reactions occurred in patients undergoing CIT. Conclusions: CIT maintenance therapy in ES-SCLC prolonged survival with only minimal side effects. Integrating CIT into the current treatment may be a novel strategy for ES-SCLC patients, although further multi-center randomized trials are needed.
推荐引用方式
GB/T 7714：

Ding X,Cao H,Chen X, et al. Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer in extensive stage [J].Journal of Cellular Immunotherapy,2016,2(1):36-43.
APA：

Ding X,Cao H,Chen X,Zhao Y,&Cui J.(2016).Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer in extensive stage .Journal of Cellular Immunotherapy,2(1):36-43.
MLA：

Ding X, et al. "Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer in extensive stage" .Journal of Cellular Immunotherapy 2,1(2016):36-43.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：10  下载次数：0

分享到：

浏览次数：10

下载次数：0

打印次数：0